Up to 50% of epithelial ovarian cancers (EOC) display defects in the homologous recombination (HR) pathway. We sought to determine the ramifications of the homologous recombination deficient (HRD) status on the clinicopathological features, chemotherapy response and survival outcomes of EOC patients. HR status was determined in primary cultures from ascitic fluid in 50 chemotherapy naïve patients by a functional RAD51 immunofluorescence assay and correlated with in vitro sensitivity to the PARP inhibitor (PARPi), rucaparib. All patients went on to receive platinum based chemotherapy; platinum sensitivity, tumor progression and overall survival were compared prospectively in HR competent vs. HR deficient patients. Compared to HR competent patients, the HRD group was predominantly serous with a higher median CA125 at presentation. HRD was associated with higher ex vivo PARP inhibitor sensitivity and clinical platinum sensitivity. Median follow up duration was 14 months; patients in the HRD group had lower tumor progression rates at 6 months, lower overall /disease specific death rates at 12 months and higher median survival. We therefore suggest that HRD as predicted by a functional RAD51 assay correlates with in vitro PARPi sensitivity, clinical platinum sensitivity and improved survival outcome.
Introduction
Approximately ten percent of epithelial ovarian cancers (EOCs) have germ line mutations in BRCA1/ BRCA 2 rendering them deficient in the homologous recombination (HR) DNA repair pathway 1, 2 . A majority of studies show an improved overall and progression free survival compared to non BRCA related sporadic EOCs 3, 4, 5 . BRCAness is a term which has been coined to describe cancers which do not have mutations in BRCA genes but phenotypically behave like these tumours due to genetic/epigenetic events 6 . These aberrations may render these tumours defective in homologous recombination and therefore HRD (homologous recombination deficiency) would appear to be a more appropriate terminology. It is estimated that up to 50-60% EOCs could be HRD;
functional assays continue to be developed to identify this subset of EOCs 7 . A recent study analyzing retrospective data showed that EOCs with "BRCAness" determined by gene expression profiling had improved disease free survival compared to non BRCA like tumours 8 . However, these data need to be confirmed in prospective studies.
There is now widespread agreement that a novel class of anticancer agents, PARP Author Manuscript Published OnlineFirst on October 11, 2012; DOI: 10.1158/0008-5472. shown to have increased sensitivity to platinum based chemotherapy compared to non BRCA related cancers 13 .
It would appear therefore, that EOCs with HRD are a subset of tumours which have distinct clinicopathological features, chemosensitivity and survival profiles. We developed a functional assay in primary cultures to classify EOCs based on HR status and correlated with in vitro sensitivity to PARP inhibitors 7 . All these patients subsequently received platinum based chemotherapy and were followed up. In this prospective study we aimed to correlate HR status with chemo-responsiveness and clinical outcome.
Methods
Patients with advanced stage ovarian/ primary peritoneal cancer were enrolled in this study between September 2008 through June 2010.
Ascitic fluid was collected from chemotherapy naïve patients, either those undergoing primary surgery or those undergoing paracentesis prior to receiving chemotherapy.
Ethical approval and specific consent was obtained for collection of clinical material and clinical information. None of the patients had been screened for BRCA mutations or selected on the basis of a family history of breast or ovarian cancer.
Determination of HR status and ex vivo cytotoxicity to PARP inhibitor.
Details of methods have been described in our previous publication (Mukhopadhyay, 2010) 7 . Primary cultures were developed successfully from ascitic fluid in > 90% cases.
HR function was determined by an immunofluorescence based assay which detects nuclear ȖH2AX foci as a marker of DNA double strand breaks (DSB) and RAD51 foci as to the HR status of the tumours. The original scoring estimated the percent of cells stained, using a six point scale, (none, <10%, 10-25%, 25-50%, 50-75% and >75%), and also the intensity of staining, (weak, moderate, strong). A modified H-score was generated by multiplying the area score with the intensity score giving a range of score from 1-18. A score of 4, was considered to be the cut off point for a negative BRCA1 IHC staining. This score was chosen as it correlates with the 10% cut off used in previous work 16 .
Patients underwent maximal effort primary cytoreductive surgery or neoadjuvant chemotherapy followed by interval debulking surgery. All surgeries were carried out by accredited Gynaecologic Oncologists. The following definitions were used for cytoreduction; complete-no visible residual disease, optimal-residual disease <1 cm maximum diameter and suboptimal -> 1 cm residual disease. 19 .
Definitions used for survival data
Survival data were calculated using the date of diagnosis, defined as the date of histological or cytological confirmation of epithelial ovarian cancer. For overall survival (OS), patients who died at follow up (any cause) were considered uncensored, whereas patients alive at follow up were censored 20 . analyses, significant differences were set as P< 0.05 at the 2-sided test (SPSS version 15.0). Demographic characters: Demographic data were available for all patients. 50 patients with epithelial ovarian/primary peritoneal cancer (HR competent, n=24; HR deficient, n=26), who completed follow up for at least 6 months after completion of chemotherapy (till April 2011) were included in the present study for analysis of clinicopathological variables (Table 1) , platinum sensitivity (Table 2 ) and survival data ( Table 3) . patients had high grade (n=44/50), advanced stage III/IV disease (n=47/50) and serous (n=39/50) carcinomas. The HRD group was predominantly serous compared to the HR competent patients (92.3% vs. 62.5%, p=0.035). Both the non-serous tumours seen in the HRD group were of high grade endometrioid type. In keeping with the higher prevalence of serous tumours and PPCs, the median CA125 at presentation was also significantly higher in the HRD group (2079 U/ml vs. 427 U/ml, p=0.007). BRCA1 IHC was negative (H score of 4) in 8/23 (34.8%) of HR deficient tumours and negative in 5/22 (22.7%) of HR competent tumours (p=0.37) ( Table 1 ).
Statistical analyses

Results
Between
Treatment modality:
The majority of patients (n=31/50) had primary surgery followed by chemotherapy, while the rest (n=18/50) were treated with 3 cycles of neo-adjuvant chemotherapy followed by interval debulking surgery and further 3 cycles of chemotherapy. One patient in the HRD group opted not to have any surgery and had 6 cycles of chemotherapy only. One patient in the HR competent group died 2 months after primary surgery, and therefore did not have any chemotherapy.
The median duration of follow up was 14 months in both groups. The majority of women received both platinum (carboplatin) and paclitaxel combination as 1st line for the whole duration of chemotherapy (n=40/50). Eight out of 50 women developed toxicity/allergy to paclitaxel during therapy and therefore went on to receive platinum only and 2 patients with stage 1c disease received 6 cycles of carboplatin as single agent therapy. 45/50 women completed 6 cycles (4 women died while on chemotherapy and one after primary surgery). At the time of final follow up, 46% women had gone on to receive 2 nd line chemotherapy and 25% of them further progressed to receive 3 rd line chemotherapy.
Chemo-response and sensitivity to Platinum: Overall 39/50 (78%) women showed evidence of response to first line chemotherapy as defined above. Women in the HRD group had a higher proportion of platinum sensitive disease compared to the HR competent group (53.8% vs. 16.7%; p= 0.063) with an increased median platinum free interval (6 months vs. 4 months). Conversely, 75% of women in the HR competent group had platinum resistant or refractory disease ( Table 2) .
Correlation between in vivo platinum sensitivity and ex vivo sensitivity to PARP inhibitor:
Sensitivity to 10μM rucaparib was seen in 24/26 (92.8%) HR deficient cultures compared to none of the 24 HR competent cultures (P <0.001) ( Table 2 ). There was a correlation between ex vivo sensitivity to PARP inhibition and in vivo platinum sensitivity (Spearman's rho, p=0.05). Out of 23 patients with ex vivo response to PARP inhibitor, 52% were platinum sensitive. Conversely, out of 23 patients showing no response to ex vivo PARP inhibition, 78.3% had platinum resistant/refractory disease.
Survival: At 12 months, tumour progression was seen in 32 out of 50 (64%) patients (Table 3) . However, at 6 months, 7.7% women in the HRD group relapsed or progressed compared to 33.3% in the HR competent group (p=0.024). Median PFS was longer in women with HRD tumours (11 months vs. 8 months) and was statistically significant (Table 4) .
HRD conferred a 70% reduction in relative risk of death at 12 months compared to HR competent patients after adjusting for stage of disease, although this was not statistically significant. Although not reaching statistical significance, patients who had suboptimal cytoreduction had increased mortality at 12 months compared to optimal or complete cytoreduction (42.9% vs. 19.4%, p=0.090) as did women with a non serous histology compared to serous tumours (45.5% vs. 20.5%, p=0.096).
Discussion
In line with our previous findings 7 approximately 50% of epithelial ovarian cancers are homologous recombination deficient (HRD) and show ex vivo cytotoxicity to a PARP 
inhibitor in more than 90% cases. These findings are consistent with other published data from the cancer genome atlas project which used molecular pathway analysis of genetic aberrations to conclude that approximately 50% of high grade serous cancers will have defective HR 21 .
These data further support the clinical use of PARP inhibitors in this group of patients, supporting data from the recently reported study of maintenance PARPi treatment with olaparib in this group 22 . Conversely, we would predict that cancers which do not have HRD are unlikely to respond to this class of agents.
We also conclude that HRD epithelial ovarian cancer as a group has a distinct clinicopathological phenotype compared to HR competent EOCs; they are predominantly serous, show increased sensitivity to platinum and tend to be associated with improved survival.
The results from our study are consistent with the prediction of the proportion of "BRCAness" phenotype expected in sporadic cancers as described by . Our study also demonstrates a correlation between HRD status, ex vivo PARP inhibitor sensitivity and clinical platinum sensitivity. An interesting group to study would appear to be women whose ascitic fluid cultures suggest that they would be sensitive to a PARP inhibitor but were shown to be platinum resistant/refractory (14/32 women in our study). Whether in recurrent EOCs, administration of PARP inhibitor helps to regain chemosensitivity to platinum based chemotherapy is currently being studied 37 .
The strength of our study in terms of clinicopathological and survival data is that it was a prospective study. Although not randomized, clinicians involved in managing the patients as regards to surgery or chemotherapy were not aware of the HR status. Also blinding was maintained at time of clinical data collection and analysis. The HRD group was predominantly serous, associated with a higher proportion of primary peritoneal cancers and higher CA125 at presentation which fits with our prediction that HRD phenotype is similar to BRCA deficient tumours. Although patients were not screened for genetic testing nor presented with known mutations except one woman in the HRD group who was subsequently found to have a germline BRCA2 mutation, a higher proportion of women in the HRD group had a family history of breast /ovarian cancers in 1 st degree relatives (33%) as well as a past history of breast cancer. It is possible to postulate with these data that HR competence confers a biologically aggressive phenotype that leads to tumours presenting at higher stage, poor histological subtypes, poor surgical resectibility and chemo resistance. There was very poor correlation with the BRCA1 status on IHC and the HR status. Only 35% of HRD tumours were negative for BRCA1
immunostaining implying other defects in the HR pathway such as a BRCA2 defect and further validates the need for development of a functional assay for HR.
Retrospective studies with long term patient follow up have indicated a significant overall survival (OS) benefit of 72 months vs 41 months in patients with a BRCA-like profile on gene expression analysis 8 . Our study will need long term follow up with the ongoing increase in patients numbers to show a statistically relevant difference. However, in advanced EOCs, even short term endpoints like tumour progression at 6 months or OS at 12 months are clinically relevant especially taking into account that the majority of women (up to 75%) are likely to develop disease progression and die from the disease 38 .
At these intervals, our data suggest a trend towards a survival benefit in the HRD group. Legends to Tables and Figures   Table 1 Clinicopathological characteristics in all women (n=50) Table 2 . Chemosensitivity to PARP inhibitor (PARPi) and platinum. Platinum sensitivity was defined as no disease recurrence within 6 months of completion of platinum based chemothaerapy. Resistance to PARPi was defined as > 70% cell survival in ex vivo cytotoxicity assays in response to 10 ȝM rucaparib.
Table3. Tumour progression rate and Overall survival (OS) in HR competent vs. HR deficient group. 
